Theratechnologies (TSE:TH) has released an update.
Theratechnologies Inc., a biopharmaceutical company, has announced its Q1 2024 financial results, reporting $16.2 million in revenue and a continued trend of near-flat-to-positive Adjusted EBITDA, projecting steady growth with full-year revenue guidance of $87 to $90 million. Despite a dip in revenue for the quarter, the company demonstrates bottom-line improvement and is advancing its oncology program, notably with the accelerated Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer. This forward momentum is expected to enhance shareholder value and facilitate strategic acquisitions.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
